Cargando…

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Detalles Bibliográficos
Autores principales:	Bock, Allison, Mwangi, Raphael, Ataei, Fatemeh, Thorpe, Matthew, Maurer, Matthew, Pritchett, Josh, Shreve, Jacob, Paludo, Jonas, Cerhan, James, Khurana, Arushi, Witzig, Thomas, Habermann, Thomas, Wang, Yucai, Nowakowski, Grzegorz S., Young, Jason
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430958/ http://dx.doi.org/10.1097/01.HS9.0000971504.65835.52

Ejemplares similares

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
por: Arushi Khurana, et al.
Publicado: (2021)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
por: Bock, A., et al.
Publicado: (2022)

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022)

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis
por: Desai, Sanjal H., et al.
Publicado: (2022)

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
por: Castellino, Alessia, et al.
Publicado: (2021)

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
por: Desai, Sanjal H., et al.
Publicado: (2022)

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials
por: Wang, Yucai, et al.
Publicado: (2022)

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
por: Bock, Allison M., et al.
Publicado: (2023)

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
por: Krull, Jordan E., et al.
Publicado: (2020)

Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
por: Bezerra, Evandro D., et al.
Publicado: (2022)

Polymorphisms in DNA Repair and One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma
por: Wang, Sophia S, et al.
Publicado: (2008)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
por: Bock, A., et al.
Publicado: (2022)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
por: Sun, Na, et al.
Publicado: (2015)

A 1152 channel timing system for an electromagnetic calorimeter readout
por: Bonesini, M, et al.
Publicado: (1987)

1152. Characteristics of Patients with Invasive Infections Caused by Trichosporon asahii
por: Kim, Jinyeong, et al.
Publicado: (2020)

1152. Microbiology of Pediatric Neck Infections Based on Age and Anatomic Location
por: Dimo, Joana, et al.
Publicado: (2021)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria
por: King, Rebecca L., et al.
Publicado: (2021)

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
por: Wang, Yucai, et al.
Publicado: (2019)

The significance of gradient expression of chromosome region maintenance protein 1 in large cell lymphoma
por: Abeykoon, Jithma P., et al.
Publicado: (2021)

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
por: Tracy, Sean I., et al.
Publicado: (2018)

P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY
por: Shah, Nirav, et al.
Publicado: (2023)

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
por: Ayed, Ayed O., et al.
Publicado: (2018)

HPLC Method for Determination of Enantiomeric Purity of a Novel Respiratory Fluoroquinolone: WCK 1152
por: Yeole, R. D., et al.
Publicado: (2008)

1152. Quantifying the health equity related public health impact of national immunisation programmes
por: Biundo, Eliana, et al.
Publicado: (2023)

The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel
por: Wudhikarn, Kitsada, et al.
Publicado: (2021)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

1152. Leveraging Human Factors Engineering to Optimize Low-level Disinfection of Bedside Medical Tools
por: Handy, Lori, et al.
Publicado: (2018)

1152. Implementation of Enhanced Data Surveillance Methods to Reduce Catheter-Associated Urinary Tract Infections
por: Ehni, Jordan, et al.
Publicado: (2019)

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma
por: Nowakowski, Grzegorz, et al.
Publicado: (2022)

History of autoimmune conditions and lymphoma prognosis
por: Kleinstern, Geffen, et al.
Publicado: (2018)

Interim and end‐of‐treatment PET‐CT suffers from high false‐positive rates in DLBCL: Biopsy is needed prior to treatment decisions
por: Tokola, Susanna, et al.
Publicado: (2021)

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
por: Breen, William G., et al.
Publicado: (2023)

Assessment of Echinococcus multilocularis surveillance reports submitted in 2017 in the context of Commission Regulation (EU) No 1152/2011
por: Beltrán‐Beck, Beatriz, et al.
Publicado: (2017)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

DLBCL Coast to Coast
por: Tesio, Melania
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_do4c4f8qf20dj1b1gq5blrt2am